Related Experiment Video
Updated: Jun 1, 2026
07:15
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Update on nephrogenic systemic fibrosis: are we making progress?
Anna K Haemel1, Elizabeth A Sadowski, Martin M Shafer
1Departments of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
International Journal of Dermatology
|May 21, 2011
Summary
Nephrogenic systemic fibrosis (NSF) is linked to gadolinium contrast agents in patients with kidney problems. Emerging research explores the roles of contrast agents, renal dysfunction, and inflammation in NSF development.
Area of Science:
- Nephrology
- Radiology
- Toxicology
Background:
- Nephrogenic systemic fibrosis (NSF) is a rare fibrotic disorder.
- NSF is associated with gadolinium-based contrast agents (GBCAs) in patients with renal dysfunction.
- The precise determinants of NSF remain unclear, despite a small proportion of at-risk patients developing the condition.
Purpose of the Study:
- To provide an update on emerging evidence regarding the role of GBCAs, renal dysfunction, and background inflammation in NSF.
- To focus on current experimental models for understanding NSF pathophysiology.
- To summarize recent developments and discuss implications for clinical practice and future research.
Main Methods:
- Review of emerging evidence on NSF.
- Focus on current experimental models.
- Synthesis of findings on GBCAs, renal dysfunction, and inflammation.
Main Results:
- Significant progress has been made in understanding NSF pathophysiology.
- Emerging evidence highlights the interplay of GBCAs, renal dysfunction, and inflammation in NSF.
- Current experimental models are advancing the understanding of disease mechanisms.
Conclusions:
- Recent research has improved the understanding of NSF pathophysiology.
- The findings have implications for clinical practice regarding GBCA use in at-risk patients.
- Further study is needed to fully elucidate NSF development and prevention strategies.
Related Concept Videos
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Cystic Fibrosis: Management
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Sinus disease and chronic sinusitis...
01:29Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...